Logotype for Morphic Holding Inc

Morphic Holding (MORF) investor relations material

Morphic Holding Jefferies 2024 Global Healthcare Conference summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Morphic Holding Inc
Jefferies 2024 Global Healthcare Conference summary5 Jun, 2024

Key program updates

  • Morphic's ulcerative colitis Phase 2b trial is enrolling well, with strong confidence in meeting guidance for data in the first half of 2025.

  • Enrollment strategy balances biologic-naive and experienced patients, targeting a representative mix and at least 30% advanced therapy-experienced participants.

  • The oral alpha-4 beta-7 candidate is positioned as a differentiated, safe, and effective therapy, aiming for an approvable agent with a placebo-adjusted remission rate in the 10–15% range.

  • Phase 2a data showed strong safety, full receptor occupancy, and promising efficacy, with 25–26% remission in modified Mayo scores, though some controversy remains over endoscopic data.

  • A Crohn's disease study has been initiated and is in early enrollment, with updates expected as screening progresses.

Strategic and financial outlook

  • Morphic holds a wholly owned asset in a space with recent significant M&A activity, and is open to global partnerships if valuation is attractive.

  • Management is comfortable with its cash position, reporting around $700 million, and does not anticipate near-term financing needs.

  • Current cash runway is projected to extend well into 2027, supporting ongoing and planned clinical programs.

  • Guidance on trial timelines may be narrowed in the next six months, with an update on enrollment expected.

Competitive landscape and pipeline

  • Gilead and Takeda are pursuing similar alpha-4 beta-7 programs, with Gilead's trial design closely mirroring Morphic's; no data from Gilead's compound is available yet.

  • Morphic is advancing early-stage oral IL-23 and TL1A programs, with the IL-23 candidate at hit-to-lead stage and TL1A in early development.

  • Combination therapy strategies are being considered, with potential to follow competitors' approaches once optimal dosing is established in Phase 2b.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Morphic Holding Inc., a biopharmaceutical company, specializes in the discovery and development of oral small-molecule integrin therapeutics. These treatments are aimed at addressing a variety of serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, as well as fibrosis and cancer. A key focus of their research is on MORF-057, an α4β7 integrin inhibitor designed to modulate inflammation, currently in clinical trials for treating inflammatory bowel disease. Morphic's pipeline also explores integrin targets for other gastrointestinal indications, myelofibrosis, and solid tumors among others. The company is headquartered in Waltham, Massachusetts, and its shares are listed on the Nasdaq.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage